Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis

[41] Armangue T(2018)MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature J Neuroinflammation 15 e1250-862

[42] Martinez-Hernandez E(2007)Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein Nat Med 13 1355-487

[43] Arrambide G(2019)Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up J Neurol Neurosurg Psychiatry 90 811-16

[44] Sola-Valls N(2019)A multicenter comparison of MOG-IgG cell-based assays Neurology 92 806-29

[45] Sabater L(2018)Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders JAMA Neurol 75 419-625

[46] Jarius S(2017)Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases J Neurol Neurosurg Psychiatry 88 346-undefined

[47] Ruprecht K(2019)Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults J Neurol 266 870-undefined

[48] Kleiter I(2019)Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm 6 858-undefined

[49] Borisow N(2018)Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial JAMA Ophthalmol 136 478-undefined

[50] Asgari N(2018)Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders J Neurol Neurosurg Psychiatry 89 134-undefined

[41] Armangue T(2018)MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature J Neuroinflammation 15 e1250-862

[42] Martinez-Hernandez E(2007)Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein Nat Med 13 1355-487

[43] Arrambide G(2019)Aquaporin-4 and myelin oligodendrocyte glycoprotein antibodies in immune-mediated optic neuritis at long-term follow-up J Neurol Neurosurg Psychiatry 90 811-16

[44] Sola-Valls N(2019)A multicenter comparison of MOG-IgG cell-based assays Neurology 92 806-29

[45] Sabater L(2018)Association of MOG-IgG serostatus with relapse after acute disseminated encephalomyelitis and proposed diagnostic criteria for MOG-IgG-associated disorders JAMA Neurol 75 419-625

[46] Jarius S(2017)Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases J Neurol Neurosurg Psychiatry 88 346-undefined

[47] Ruprecht K(2019)Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults J Neurol 266 870-undefined

[48] Kleiter I(2019)Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis? Neurol Neuroimmunol Neuroinflamm 6 858-undefined

[49] Borisow N(2018)Prevalence of myelin oligodendrocyte glycoprotein and aquaporin-4-IgG in patients in the optic neuritis treatment trial JAMA Ophthalmol 136 478-undefined

[50] Asgari N(2018)Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders J Neurol Neurosurg Psychiatry 89 134-undefined